 | • レポートコード：MRC2206A026 • 出版社/出版日：Persistence Market Research / 2022年3月22日 • レポート形態：英文、PDF、213ページ • 納品方法：Eメール • 産業分類：医療 |
| Single User | ￥725,200 (USD4,900) | ▷ お問い合わせ |
| Site Licence | ￥1,124,800 (USD7,600) | ▷ お問い合わせ |
| Enterprisewide | ￥1,568,800 (USD10,600) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Persistence Market Research社の本調査レポートでは、世界の臨床試験＆製剤アウトソーシング市場について広く調査・分析し、エグゼクティブサマリー、市場概要、主要市場動向、主要成功要因、市場背景、新型コロナウイルス感染症による危機分析、需要分析・予測、製品別（経口剤、注射剤、その他）分析、用途別（API製造、充填・仕上げ製品製造、医薬品開発、包装/ラベリング、その他）分析、エンドユーザー別（製薬・バイオテクノロジー企業、栄養補助食品会社）分析、地域別分析、市場構造分析、競争分析、仮定、調査手法などの項目を掲載しております。 ・エグゼクティブサマリー ・市場概要 ・主要市場動向 ・主要成功要因 ・市場背景 ・新型コロナウイルス感染症による危機分析 ・世界の臨床試験＆製剤アウトソーシング市場規模：製品別（経口剤、注射剤、その他） ・世界の臨床試験＆製剤アウトソーシング市場規模：用途別（API製造、充填・仕上げ製品製造、医薬品開発、包装/ラベリング、その他） ・世界の臨床試験＆製剤アウトソーシング市場規模：エンドユーザー別（製薬・バイオテクノロジー企業、栄養補助食品会社） ・世界の臨床試験＆製剤アウトソーシング市場規模：地域別 ・市場構造分析 ・競争分析 ・仮定 ・調査手法 |
Outsourced Clinical Trails & Formulation Market: Scope of Report
The latest publication by Persistence Market Research on the global outsourced clinical trials & formulation market evaluates the opportunities and current market landscape and provides detailed analysis and updates about corresponding sections affecting the market. The study offers detailed insights on current market dynamics, which include the drivers, restraints, trends, and opportunities in the market. The principal aim of the market study is to present exclusive information about how the market will perform during the forecast period of 2022-2027.
Important indicators for the successful growth of the market are presented in this comprehensive report, which includes a Year-on-Year (Y-o-Y) growth analysis of the market, and compounded annual growth rate (CAGR), which are described exhaustively in Persistence Market Research’s study. This research study can support readers to know the demand for outsourced clinical trials & formulation and the quantitative development opportunities during the study period.
The research is beneficial for shareholders in the landscape, including investors, manufacturers, service providers, distributors, and suppliers, and can help them in developing suitable business strategies to flourish in the outsourced clinical trials & formulation market. Insights and information presented in this Persistence Market Research study can be leveraged by shareholders in the outsourced clinical trials & formulation market, industry experts, investors, researchers, and reporters, as well as business enthusiasts.
Market statistics, as well as information linked to the macro- as well as micro-economic variables affecting the business scenario in the outsourced clinical trials & formulation market, are also included in the current study. Depending on potential developments in the market, substantive insights are also encountered in this report. Additionally, by the data submitted in this report, minor companies and new entrants in the industry can be aided in making suitable company choices to achieve traction in the market.
Key Market Segments
Persistence Market Research’s study on the outsourced clinical trials & formulation market offers information divided into four important segments – product, application, end user, and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.
Product
Oral Dosage Forms
Solid Dosage Forms
Liquid Dosage Forms
Semi-solid Dosage Forms
Injectable Dosage Forms
Others
Application
API Manufacturing
Fill-Finish Product Manufacturing
Drug Product Development
Packaging/Labelling
Others
End User
Big Pharmaceutical /Biotech Companies
Small & Medium Size Pharma/Biotech Companies
Emerging/virtual Pharma Companies
Nutraceutical Companies
Region
North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa
Key Questions Answered in Report
Which regions will continue to remain the most profitable markets for outsourced clinical trials & formulations over the coming years?
How will changing trends impact the market?
How has the COVID-19 crisis impacted market growth?
How can market players capture the low-hanging opportunities in developed regions?
What are the strategies of stakeholders in the market to shape their position in this landscape?
What are the restraining factors that investors need to be aware of and might tackle while investing in the market?
What are the developmental trends that will impact the market?
How can companies in the outsourced clinical trials & formulation industry avail themselves the growth opportunities in developed and emerging sectors?
Research Methodology
In Persistence Market Research’s study, a unique research methodology is utilized to conduct extensive research on the growth of the outsourced clinical trials & formulation market, and reach conclusions on the future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analysts to ensure the accuracy and reliability of the conclusions.
Secondary resources referred to by analysts during the production of the market study include statistics from governmental organizations, trade journals, white papers, and internal and external proprietary databases. Analysts have interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, who contributed to the development of this report as a primary resource.
Comprehensive information acquired from primary and secondary resources acts as validation from companies in the market and makes Persistence Market Research’s projections on the growth prospects of the outsourced clinical trials & formulation market are more accurate and reliable.
レポート目次1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation/ Development Trends
4. Key Success factors
4.1. Key Strategies Adopted by market players
4.2. Porters Analysis
4.3. PESTLE Analysis
4.4. Key Regulations
4.5. Value Chain Analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Healthcare Outlook
5.2. Forecast Factors – Relevance & Impact
5.2.1. Rising Geriatric Population
5.2.2. Rising incidence of Chronic Diseases
5.2.3. Patent Expiry and Increasing Demand For Generic Drugs
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. COVID19 Crisis Analysis
6.1. Current Perspectives on Coronavirus Outbreak
6.2. Current Economic Outlook & Recovery Scenario
6.3. COVID19 and Impact Analysis
6.3.1. Revenue By Product
6.3.2. Revenue By End User
6.3.3. Revenue By Region
7. Global Outsourced Clinical Trials & Formulation Market Demand (in Value or Size in US$ Mn) Analysis 2016-2021 and Forecast 2022-2027, by Product
7.1. Historical Market Value (US$ Mn) Analysis, 2016–2021
7.2. Current and Future Market Value (US$ Mn) Projections, 2022–2027
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Outsourced Clinical Trials & Formulation Market Analysis 2016-2021 and Forecast 2022-2027, by Product
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Mn) Analysis By Product, 2016-2021
8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Product, 2022-2027
8.3.1. Oral Dosage Products
8.3.1.1. Solid dosage Product
8.3.1.2. Liquid Dosage Product
8.3.1.3. Semi-solid Dosage Product
8.3.2. Injectable Dosage Product
8.3.3. Others
8.4. Market Attractiveness Analysis By Product
9. Global Outsourced Clinical Trials & Formulation Market Analysis 2016-2021 and Forecast 2022-2027, by Application
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Mn) Analysis By Application, 2016-2021
9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Application, 2022-2027
9.3.1. API Manufacturing
9.3.2. Fill Finish Product Manufacturing
9.3.3. Drug Product Development
9.3.4. Packaging / Labelling
9.3.5. Others
9.4. Market Attractiveness Analysis By Application
10. Global Outsourced Clinical Trials & Formulation Market Analysis 2016-2021 and Forecast 2022-2027, by End User
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Mn) Analysis By End User, 2016-2021
10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By End User, 2022 – 2027
10.3.1. Big Pharmaceutical and Biotech Companies
10.3.2. Small and Medium Size Pharma/Biotech Companies
10.3.3. Emerging/Virtual Pharma Companies
10.3.4. Nutraceutical Companies
10.4. Market Attractiveness Analysis By End User
11. Global Outsourced Clinical Trials & Formulation Market Analysis 2016-2021 and Forecast 2022-2027, by Region
11.1. Introduction
11.2. Historical Market Size (US$ Mn) Analysis By Region, 2016-2021
11.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2022 – 2027
11.3.1. North America
11.3.2. Europe
11.3.3. Asia pacific
11.3.4. Rest of the World
11.4. Market Attractiveness Analysis By Region
12. North America Outsourced Clinical Trials & Formulation Market Analysis 2016-2021 and Forecast 2022-2027
12.1. Introduction
12.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2021
12.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2027
12.3.1. By Country
12.3.1.1. U.S.
12.3.1.2. Canada
12.3.2. By Product
12.3.3. By Application
12.3.4. By End User
12.4. Market Attractiveness Analysis
12.5. Drivers and Restraints – Impact Analysis
13. Europe Outsourced Clinical Trials & Formulation Market Analysis 2016-2021 and Forecast 2022-2027
13.1. Introduction
13.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2021
13.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2027
13.3.1. By Country
13.3.1.1. U.K.
13.3.1.2. Germany
13.3.1.3. France
13.3.1.4. Italy
13.3.1.5. Spain
13.3.1.6. BENELUX
13.3.1.7. Russia
13.3.1.8. BENELUX
13.3.1.9. Rest of Europe
13.3.2. By Product
13.3.3. By Application
13.3.4. By End User
13.4. Market Attractiveness Analysis
13.5. Drivers and Restraints – Impact Analysis
14. Asia Pacific Outsourced Clinical Trials & Formulation Market Analysis 2016-2021 and Forecast 2022-2027
14.1. Introduction
14.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2021
14.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2027
14.3.1. By Country
14.3.1.1. China
14.3.1.2. Japan
14.3.1.3. South Korea
14.3.1.4. India
14.3.1.5. Australia and New Zealand
14.3.1.6. ASEAN
14.3.1.7. Rest of Asia Pacific
14.3.2. By Product
14.3.3. By Application
14.3.4. By End User
14.4. Market Attractiveness Analysis
14.5. Drivers and Restraints – Impact Analysis
15. Rest of the World Outsourced Clinical Trials & Formulation Market Analysis 2016-2021 and Forecast 2022-2027
15.1. Introduction
15.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2021
15.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2027
15.3.1. By Product
15.3.2. By Application
15.3.3. By End User
15.4. Market Attractiveness Analysis
15.5. Drivers and Restraints – Impact Analysis
16. Market Structure Analysis
16.1. Market Analysis y Tier of Companies
16.2. Market Share Analysis of Top Players
17. Competition Analysis
17.1. Competition Dashboard
17.2. Competition Benchmarking
17.3. Competition Deep Dive (Tentative List)
17.3.1. Lonza Group
17.3.1.1. Overview
17.3.1.2. Product Portfolio
17.3.1.3. Key Financials
17.3.1.4. SWOT Analysis
17.3.1.5. Sales Footprint
17.3.1.6. Strategy Overview
17.3.2. Catalent, Inc.
17.3.2.1. Overview
17.3.2.2. Product Portfolio
17.3.2.3. Key Financials
17.3.2.4. SWOT Analysis
17.3.2.5. Sales Footprint
17.3.2.6. Strategy Overview
17.3.3. Thermo Fisher Scientific Inc. (Patheon)
17.3.3.1. Overview
17.3.3.2. Product Portfolio
17.3.3.3. Key Financials
17.3.3.4. SWOT Analysis
17.3.3.5. Sales Footprint
17.3.3.6. Strategy Overview
17.3.4. Piramal Pharma Solutions
17.3.4.1. Overview
17.3.4.2. Product Portfolio
17.3.4.3. Key Financials
17.3.4.4. SWOT Analysis
17.3.4.5. Sales Footprint
17.3.4.6. Strategy Overview
17.3.5. BioXcellence (Boehringer Ingelheim International GmbH)
17.3.5.1. Overview
17.3.5.2. Product Portfolio
17.3.5.3. Key Financials
17.3.5.4. SWOT Analysis
17.3.5.5. Sales Footprint
17.3.5.6. Strategy Overview
17.3.6. Siegfried Holding AG
17.3.6.1. Overview
17.3.6.2. Product Portfolio
17.3.6.3. Key Financials
17.3.6.4. SWOT Analysis
17.3.6.5. Sales Footprint
17.3.6.6. Strategy Overview
17.3.7. Evotec A.G.
17.3.7.1. Overview
17.3.7.2. Product Portfolio
17.3.7.3. Key Financials
17.3.7.4. SWOT Analysis
17.3.7.5. Sales Footprint
17.3.7.6. Strategy Overview
17.3.8. Ascendia Pharmaceuticals
17.3.8.1. Overview
17.3.8.2. Product Portfolio
17.3.8.3. Key Financials
17.3.8.4. SWOT Analysis
17.3.8.5. Sales Footprint
17.3.8.6. Strategy Overview
17.3.9. Experic Services
17.3.9.1. Overview
17.3.9.2. Product Portfolio
17.3.9.3. Key Financials
17.3.9.4. SWOT Analysis
17.3.9.5. Sales Footprint
17.3.9.6. Strategy Overview
17.3.10. Quotient Sciences
17.3.10.1. Overview
17.3.10.2. Product Portfolio
17.3.10.3. Key Financials
17.3.10.4. SWOT Analysis
17.3.10.5. Sales Footprint
17.3.10.6. Strategy Overview
17.3.11. Velesco Pharmaceutical Services, Inc.
17.3.11.1. Overview
17.3.11.2. Product Portfolio
17.3.11.3. Key Financials
17.3.11.4. SWOT Analysis
17.3.11.5. Sales Footprint
17.3.11.6. Strategy Overview
17.3.12. Elements Group (Avomeen)
17.3.12.1. Overview
17.3.12.2. Product Portfolio
17.3.12.3. Key Financials
17.3.12.4. SWOT Analysis
17.3.12.5. Sales Footprint
17.3.12.6. Strategy Overview
17.3.13. VxP Pharma
17.3.13.1. Overview
17.3.13.2. Product Portfolio
17.3.13.3. Key Financials
17.3.13.4. SWOT Analysis
17.3.13.5. Sales Footprint
17.3.13.6. Strategy Overview
17.3.14. Adare Pharmaceuticals, Inc.
17.3.14.1. Overview
17.3.14.2. Product Portfolio
17.3.14.3. Key Financials
17.3.14.4. SWOT Analysis
17.3.14.5. Sales Footprint
17.3.14.6. Strategy Overview
17.3.15. KP Pharmaceutical Technology Inc.
17.3.15.1. Overview
17.3.15.2. Product Portfolio
17.3.15.3. Key Financials
17.3.15.4. SWOT Analysis
17.3.15.5. Sales Footprint
17.3.15.6. Strategy Overview
17.3.16. Enteris Biopharma, Inc.
17.3.16.1. Overview
17.3.16.2. Product Portfolio
17.3.16.3. Key Financials
17.3.16.4. SWOT Analysis
17.3.16.5. Sales Footprint
17.3.16.6. Strategy Overview
17.3.17. Aenova Holding GmbH
17.3.17.1. Overview
17.3.17.2. Product Portfolio
17.3.17.3. Key Financials
17.3.17.4. SWOT Analysis
17.3.17.5. Sales Footprint
17.3.17.6. Strategy Overview
17.3.18. Ardena Holding NV
17.3.18.1. Overview
17.3.18.2. Product Portfolio
17.3.18.3. Key Financials
17.3.18.4. SWOT Analysis
17.3.18.5. Sales Footprint
17.3.18.6. Strategy Overview
17.3.19. Pharmaceutics International, Inc.
17.3.19.1. Overview
17.3.19.2. Product Portfolio
17.3.19.3. Key Financials
17.3.19.4. SWOT Analysis
17.3.19.5. Sales Footprint
17.3.19.6. Strategy Overview
17.3.20. Alcami Corporation, Inc.
17.3.20.1. Overview
17.3.20.2. Product Portfolio
17.3.20.3. Key Financials
17.3.20.4. SWOT Analysis
17.3.20.5. Sales Footprint
17.3.20.6. Strategy Overview
17.3.21. NextPharma Technologies
17.3.21.1. Overview
17.3.21.2. Product Portfolio
17.3.21.3. Key Financials
17.3.21.4. SWOT Analysis
17.3.21.5. Sales Footprint
17.3.21.6. Strategy Overview
17.3.22. Corden Pharma International GmbH
17.3.22.1. Overview
17.3.22.2. Product Portfolio
17.3.22.3. Key Financials
17.3.22.4. SWOT Analysis
17.3.22.5. Sales Footprint
17.3.22.6. Strategy Overview
17.3.23. Corerx, Inc.
17.3.23.1. Overview
17.3.23.2. Product Portfolio
17.3.23.3. Key Financials
17.3.23.4. SWOT Analysis
17.3.23.5. Sales Footprint
17.3.23.6. Strategy Overview
17.3.24. Recipharm AB
17.3.24.1. Overview
17.3.24.2. Product Portfolio
17.3.24.3. Key Financials
17.3.24.4. SWOT Analysis
17.3.24.5. Sales Footprint
17.3.24.6. Strategy Overview
17.3.25. Pace Analytical Services, LLC
17.3.25.1. Overview
17.3.25.2. Product Portfolio
17.3.25.3. Key Financials
17.3.25.4. SWOT Analysis
17.3.25.5. Sales Footprint
17.3.25.6. Strategy Overview
17.3.26. Almac Group, Inc.
17.3.26.1. Overview
17.3.26.2. Product Portfolio
17.3.26.3. Key Financials
17.3.26.4. SWOT Analysis
17.3.26.5. Sales Footprint
17.3.26.6. Strategy Overview
17.3.27. Cambrex Corporation
17.3.27.1. Overview
17.3.27.2. Product Portfolio
17.3.27.3. Key Financials
17.3.27.4. SWOT Analysis
17.3.27.5. Sales Footprint
17.3.27.6. Strategy Overview
17.3.28. Rottendorf Pharma GmbH
17.3.28.1. Overview
17.3.28.2. Product Portfolio
17.3.28.3. Key Financials
17.3.28.4. SWOT Analysis
17.3.28.5. Sales Footprint
17.3.28.6. Strategy Overview
17.3.29. Glatt GmbH
17.3.29.1. Overview
17.3.29.2. Product Portfolio
17.3.29.3. Key Financials
17.3.29.4. SWOT Analysis
17.3.29.5. Sales Footprint
17.3.29.6. Strategy Overview
17.3.30. Hovione
17.3.30.1. Overview
17.3.30.2. Product Portfolio
17.3.30.3. Key Financials
17.3.30.4. SWOT Analysis
17.3.30.5. Sales Footprint
17.3.30.6. Strategy Overview
17.3.31. Aphena Pharma Solutions
17.3.31.1. Overview
17.3.31.2. Product Portfolio
17.3.31.3. Key Financials
17.3.31.4. SWOT Analysis
17.3.31.5. Sales Footprint
17.3.31.6. Strategy Overview
17.3.32. HERMES PHARMA GmbH
17.3.32.1. Overview
17.3.32.2. Product Portfolio
17.3.32.3. Key Financials
17.3.32.4. SWOT Analysis
17.3.32.5. Sales Footprint
17.3.32.6. Strategy Overview
18. Assumptions and Acronyms Used
19. Research Methodology
Table 01: Global Outsourced Clinical Trials & Formulation Market Size Analysis (US$ Mn) Analysis 2016-2021 and Forecast 2022 – 2027, By ProductTable 02: Global Outsourced Clinical Trials & Formulation Market Size Analysis (US$ Mn) Analysis 2016-2021 and Forecast 2022 – 2027, By Application
Table 03: Global Outsourced Clinical Trials & Formulation Market Size Analysis (US$ Mn) Analysis 2016-2021 and Forecast 2022 – 2027, By End User
Table 04: Global Outsourced Clinical Trials & Formulation Market Size Analysis (US$ Mn) Analysis 2016-2021 and Forecast 2022 – 2027, By Region
Table 05: North America Outsourced Clinical Trials & Formulation Market Size (US$ Mn) Analysis 2016-2021 and Forecast 2022-2027, By Product
Table 06: North America Outsourced Clinical Trials & Formulation Market Size (US$ Mn) Analysis 2016-2021 and Forecast 2022-2027, By Application
Table 07: North America Outsourced Clinical Trials & Formulation Market Size (US$ Mn) Analysis 2016-2021 and Forecast 2022-2027, By End User
Table 08: Europe Outsourced Clinical Trials & Formulation Market Size (US$ Mn) Analysis 2016-2021 and Forecast 2022-2027, By Product
Table 09: Europe Outsourced Clinical Trials & Formulation Market Size (US$ Mn) Analysis 2016-2021 and Forecast 2022-2027, By Application
Table 10: Europe Outsourced Clinical Trials & Formulation Market Size (US$ Mn) Analysis 2016-2021 and Forecast 2022-2027, By End User
Table 11: Asia Pacific Outsourced Clinical Trials & Formulation Market Size (US$ Mn) Analysis 2016-2021 and Forecast 2022-2027, By Product
Table 12: Asia Pacific Outsourced Clinical Trials & Formulation Market Size (US$ Mn) Analysis 2016-2021 and Forecast 2022-2027, By Application
Table 13: Asia Pacific Outsourced Clinical Trials & Formulation Market Size (US$ Mn) Analysis 2016-2021 and Forecast 2022-2027, By End User
Table 14: Rest of the World Outsourced Clinical Trials & Formulation Market Size (US$ Mn) Analysis 2016-2021 and Forecast 2022-2027, By Product
Table 15: Rest of the World Outsourced Clinical Trials & Formulation Market Size (US$ Mn) Analysis 2016-2021 and Forecast 2022-2027, By Application
Table 16: Rest of the World Outsourced Clinical Trials & Formulation Market Size (US$ Mn) Analysis 2016-2021 and Forecast 2022-2027, By End User